ZA962248B - Nanususpensions for intravenous administration - Google Patents
Nanususpensions for intravenous administrationInfo
- Publication number
- ZA962248B ZA962248B ZA962248A ZA962248A ZA962248B ZA 962248 B ZA962248 B ZA 962248B ZA 962248 A ZA962248 A ZA 962248A ZA 962248 A ZA962248 A ZA 962248A ZA 962248 B ZA962248 B ZA 962248B
- Authority
- ZA
- South Africa
- Prior art keywords
- nanususpensions
- intravenous administration
- intravenous
- administration
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/08—Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
- G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
- G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
- G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
- G06K19/0723—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Business, Economics & Management (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Economics (AREA)
- Dermatology (AREA)
- Development Economics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Entrepreneurship & Innovation (AREA)
- Human Resources & Organizations (AREA)
- Marketing (AREA)
- Operations Research (AREA)
- Quality & Reliability (AREA)
- Strategic Management (AREA)
- Tourism & Hospitality (AREA)
- Neurosurgery (AREA)
- General Business, Economics & Management (AREA)
- Neurology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH80495 | 1995-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA962248B true ZA962248B (en) | 1996-09-23 |
Family
ID=4195580
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA962248A ZA962248B (en) | 1995-03-21 | 1996-03-20 | Nanususpensions for intravenous administration |
ZA962249A ZA962249B (en) | 1995-03-21 | 1996-03-20 | Pharmaceutical carriers for nanosuspensions |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA962249A ZA962249B (en) | 1995-03-21 | 1996-03-20 | Pharmaceutical carriers for nanosuspensions |
Country Status (12)
Country | Link |
---|---|
US (1) | US5726164A (fr) |
EP (2) | EP0733372A3 (fr) |
JP (2) | JPH08268893A (fr) |
KR (7) | KR960034028A (fr) |
AU (2) | AU4809596A (fr) |
CA (2) | CA2172111A1 (fr) |
HU (2) | HUP9600700A3 (fr) |
IL (2) | IL117550A0 (fr) |
MX (1) | MX9601032A (fr) |
NO (2) | NO961137L (fr) |
NZ (2) | NZ286207A (fr) |
ZA (2) | ZA962248B (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0733372A3 (fr) * | 1995-03-21 | 1998-05-20 | Ciba-Geigy Ag | Base pharmaceutique pour la formulation de nanosuspensions |
US6066602A (en) * | 1997-08-07 | 2000-05-23 | Becton Dickinson And Company | Waterborne non-silicone lubricant comprising phospholipid and polyether |
US6711160B2 (en) * | 1998-03-31 | 2004-03-23 | International Business Machines Corporation | Packet network telephone interface system for POTS |
TWI241915B (en) * | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
US7795246B2 (en) * | 1998-08-06 | 2010-09-14 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
US6200968B1 (en) * | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
KR100660529B1 (ko) * | 1999-01-07 | 2006-12-22 | 삼성전자주식회사 | 통신 시스템 및 그의 제어 방법 |
GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
JP3653422B2 (ja) * | 1999-08-20 | 2005-05-25 | シャープ株式会社 | 排水処理方法および排水処理装置 |
US6979459B1 (en) | 2000-04-06 | 2005-12-27 | Perricone Nicholas V | Treatment of skin damage using polyenylphosphatidycholine |
US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
US6932963B2 (en) | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
US6623765B1 (en) | 2000-08-01 | 2003-09-23 | University Of Florida, Research Foundation, Incorporated | Microemulsion and micelle systems for solubilizing drugs |
KR20020065105A (ko) * | 2001-02-05 | 2002-08-13 | 동안엔지니어링 주식회사 | 반도체 세정폐수 중 절삭가공 폐수에서 농축, 회수된실리콘 입자의 재활용 방법 |
CA2439097C (fr) * | 2001-03-26 | 2010-10-12 | Novartis Ag | Compositions pharmaceutiques |
WO2003037347A1 (fr) | 2001-10-30 | 2003-05-08 | Novartis Ag | Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3 |
KR100422763B1 (ko) * | 2002-01-17 | 2004-03-12 | 주식회사 태평양 | 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물 |
US20040018237A1 (en) * | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
US8435942B2 (en) * | 2002-05-31 | 2013-05-07 | Transdermal Biotechnology, Inc. | Methods for formulating stabilized insulin compositions |
DE10233737A1 (de) * | 2002-07-24 | 2004-02-05 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen |
US20070191338A1 (en) | 2003-08-08 | 2007-08-16 | Atadja Peter W | Combinations comprising staurosporines |
DE102004019413A1 (de) * | 2004-04-19 | 2005-11-24 | Phenos Gmbh | Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten |
KR20050102711A (ko) * | 2004-04-21 | 2005-10-27 | 서울통신기술 주식회사 | 아이 브이 알 시스템에서의 신호처리장치 및 그 방법 |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
WO2009067221A2 (fr) * | 2007-11-20 | 2009-05-28 | Cephalon, Inc. | Microémulsion contenant un composé indolocarbazole et formes pharmaceutiques la contenant |
DK2349201T3 (en) * | 2008-10-30 | 2015-01-19 | Medlite As | Formulation for the treatment of vaginal dryness |
WO2011000811A2 (fr) * | 2009-06-30 | 2011-01-06 | Novartis Ag | Composés organiques |
EP2335686A1 (fr) * | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | Nanosuspension intraveineuse aqueuse dotée d'effets indésirables diminués |
EP2685962A1 (fr) | 2011-03-17 | 2014-01-22 | Transdermal Biotechnology, Inc. | Systèmes topiques d'oxyde nitrique et leurs procédés d'utilisation |
CN104350134B (zh) * | 2012-05-29 | 2018-03-09 | 贝克顿迪金森法国公司 | 润滑剂涂层和包含这样的涂层的医用注射装置 |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US10220026B2 (en) | 2014-08-11 | 2019-03-05 | The University Of Tokyo | Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer |
EP3319608A4 (fr) * | 2015-07-07 | 2019-04-03 | LifeRaft Biosciences, Inc. | Formulations de poloxamère-188 à teneur en sodium réduite et procédés d'utilisation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431631A (en) * | 1983-01-03 | 1984-02-14 | Colgate-Palmolive Company | Aqueous oral solution |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
JP2627158B2 (ja) * | 1987-11-20 | 1997-07-02 | ゼリア新薬工業株式会社 | 脂溶性物質の安定な水溶液 |
JP2792005B2 (ja) * | 1988-08-11 | 1998-08-27 | 竹本油脂株式会社 | 農薬粒剤用崩壊助剤及び該崩壊助剤を含有する農薬粒剤 |
JP2792006B2 (ja) * | 1988-09-22 | 1998-08-27 | 竹本油脂株式会社 | 農薬粒剤用崩壊拡展助剤及び該崩壊拡展助剤を含有する農薬粒剤 |
EP0733372A3 (fr) * | 1995-03-21 | 1998-05-20 | Ciba-Geigy Ag | Base pharmaceutique pour la formulation de nanosuspensions |
-
1996
- 1996-03-12 EP EP96810151A patent/EP0733372A3/fr not_active Withdrawn
- 1996-03-12 EP EP96810150A patent/EP0733358A3/fr not_active Withdrawn
- 1996-03-15 AU AU48095/96A patent/AU4809596A/en not_active Abandoned
- 1996-03-15 AU AU48094/96A patent/AU4809496A/en not_active Abandoned
- 1996-03-19 MX MX9601032A patent/MX9601032A/es unknown
- 1996-03-19 JP JP8063194A patent/JPH08268893A/ja active Pending
- 1996-03-19 JP JP8063092A patent/JPH08268915A/ja active Pending
- 1996-03-19 IL IL11755096A patent/IL117550A0/xx unknown
- 1996-03-19 CA CA002172111A patent/CA2172111A1/fr not_active Abandoned
- 1996-03-19 NZ NZ286207A patent/NZ286207A/en unknown
- 1996-03-19 IL IL11755196A patent/IL117551A0/xx unknown
- 1996-03-19 NZ NZ286206A patent/NZ286206A/en unknown
- 1996-03-19 CA CA002172110A patent/CA2172110A1/fr not_active Abandoned
- 1996-03-20 KR KR1019960007552A patent/KR960034028A/ko not_active Application Discontinuation
- 1996-03-20 KR KR1019960007541A patent/KR960033471A/ko not_active Application Discontinuation
- 1996-03-20 US US08/619,068 patent/US5726164A/en not_active Expired - Fee Related
- 1996-03-20 NO NO961137A patent/NO961137L/no unknown
- 1996-03-20 KR KR1019960007484A patent/KR100191221B1/ko not_active IP Right Cessation
- 1996-03-20 HU HU9600700A patent/HUP9600700A3/hu unknown
- 1996-03-20 KR KR1019960007547A patent/KR960035462A/ko active IP Right Grant
- 1996-03-20 ZA ZA962248A patent/ZA962248B/xx unknown
- 1996-03-20 KR KR1019960007545A patent/KR100194987B1/ko not_active IP Right Cessation
- 1996-03-20 ZA ZA962249A patent/ZA962249B/xx unknown
- 1996-03-20 KR KR1019960007540A patent/KR960033470A/ko not_active Application Discontinuation
- 1996-03-20 NO NO961136A patent/NO961136L/no unknown
- 1996-03-20 KR KR1019960007485A patent/KR100191219B1/ko not_active IP Right Cessation
- 1996-03-20 HU HU9600701A patent/HUP9600701A3/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA962248B (en) | Nanususpensions for intravenous administration | |
GB2303064B (en) | Medicament for nasal administration | |
PL322579A1 (en) | 2-methyl-thiene-benzodiazeoin prparation for oral administration | |
HUP9800523A3 (en) | Insulin derivatives | |
EP0971758A4 (fr) | Systeme de perfusion intraveineuse | |
EP0850057A4 (fr) | Composes pharmaceutiques | |
GB2308302B (en) | Syringe | |
GB9508823D0 (en) | Drug Derivatives | |
GB2308067B (en) | Fluid administration | |
GB9319371D0 (en) | Medication administration apparatus | |
HU9603498D0 (en) | Pharmaceutical compounds | |
GB2300121B (en) | Complete infusion set | |
GB9524722D0 (en) | Syringes | |
GB9503322D0 (en) | Medicament administration dummy | |
AUPN726895A0 (en) | Intravenous delivery | |
CA75865S (en) | Infusion package | |
CA77218S (en) | Infusion package | |
GB9526439D0 (en) | Pharmaceutical compound | |
GB9513871D0 (en) | Syringe | |
GB9524458D0 (en) | Syringe | |
IL114370A0 (en) | Syringe | |
GB9511410D0 (en) | Syringe | |
GB9503067D0 (en) | Infusion packages | |
GB9524151D0 (en) | Syringes | |
GB9522132D0 (en) | Pharmaceutical compounds |